DHCG Disruptive Dose

In this DHCG Disruptive Dose, Mark Bard speaks with David Ormesher, CEO at CG Life, about moving AI from pilots to operational reality in healthcare marketing.

In this DHCG Disruptive Dose, Mark Bard speaks with Mark Jones, Head of Sales at Perform Media, about evolving performance marketing beyond direct-response tactics…

Mark Bard speaks with Amanda Phraner, Strategic Communications Leader, about elevating communications from tactical execution to strategic business function in pharma.

Mark Bard speaks with Barbara Salami, former Novo Nordisk executive and current CEO of KAINDLY, about transforming patient-centricity from buzzword into operational reality.

Mark Bard and AstraZeneca’s Chuck Sachs discuss balancing experimentation with execution in pharma innovation.

Mark Bard and Sanofi’s Pete Dannenfelser discuss turning omnichannel strategy into a practical reality for pharmaceutical marketing.

Mark Bard, Frank Burrell, and Tim Frank of Deerfield Group discuss the convergence of AI and human creativity in healthcare marketing.

Mark Bard and McKinsey’s Nicholas Mills discuss the evolving role of AI in pharma commercial operations and how to distinguish hype from genuine transformation.

Mark Bard and Sanofi’s Randy Keim discuss implementing AI-powered personalization in pharmaceutical marketing.

Mark Bard and Blueprint Audiences founder Jeremy Mittler discuss data privacy in the context of audience targeting.

Mark Bard and Shwen Gwee discuss AI’s impact on pharma marketing, highlighting automation, integrated patient support, and the rapid adoption of ambient listening tools.

In this DHCG Disruptive Dose episode, Mark Bard of the DHC Group and RJ Lewis of eHealthcare Solutions discuss AI’s disruptive impact on the medical publishing industry.

Mark Bard and DrFirst’s Dr. Colin Banas discuss technology’s role in improving specialty care and healthcare access.